Fortress Biotech (FBIO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for June 17, 2025, to be held virtually at 10:00 AM EDT.
Shareholders can access proxy materials online or request paper/email copies by June 3, 2025.
Voting is available online until June 16, 2025, at 11:59 PM ET.
Voting matters and shareholder proposals
Election of seven directors, all recommended by the board.
Ratification of KPMG LLP as independent auditor for fiscal year ending December 31, 2025.
Advisory approval of executive compensation and frequency of future say-on-pay votes.
Approval of the Second Amended and Restated Certificate of Incorporation to include officer exculpation.
Proxy may vote on other business as may properly come before the meeting.
Board of directors and corporate governance
Nominees for director include Lindsay A. Rosenwald, Michael S. Weiss, Jimmie Harvey Jr., Malcolm Hoenlein, Dov Klein, J. Jay Lobell, and Kevin L. Lorenz.
Latest events from Fortress Biotech
- 600,000 shares registered for resale by Oaktree via warrants; no proceeds to the company.FBIO
Registration Filing18 Dec 2025 - 2.35 million shares registered for resale by stockholders; no proceeds to the company.FBIO
Registration Filing16 Dec 2025 - Virtual meeting to vote on directors, auditor, executive pay, and officer exculpation.FBIO
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, auditor, executive pay, and officer exculpation.FBIO
Proxy Filing2 Dec 2025 - Registers 6.19M shares for resale from recent financings; no proceeds to the company.FBIO
Registration Filing29 Nov 2025 - All director and compensation proposals passed; officer exculpation amendment failed.FBIO
AGM 202525 Nov 2025 - Q3 2025 revenue up 21% to $17.6M, led by Emrosi's launch, strong growth, and asset sales.FBIO
Q3 202517 Nov 2025 - Q2 2025 net income surged to $13.4M, driven by the Checkpoint sale and Emrosi's strong launch.FBIO
Q2 202514 Aug 2025 - Emrosi FDA approval and late-stage pipeline progress offset revenue and cash declines.FBIO
Q3 202413 Jun 2025